{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:15:37Z","timestamp":1772748937140,"version":"3.50.1"},"reference-count":98,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2015,3,4]]},"DOI":"10.1517\/13543784.2015.999154","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T02:04:49Z","timestamp":1422842689000},"page":"345-362","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas"],"prefix":"10.1517","volume":"24","author":[{"given":"Alice","family":"Bergamini","sequence":"first","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Leone Roberti Maggiore","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[{"name":"University of Genoa, IRCCS San Martino Hospital and National Institute for Cancer Research, Department of Obstetrics and Gynecology","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Rabaiotti","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Vigan\u00f2","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela","family":"Petrone","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"De Marzi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Candiani","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Mangili","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,2]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.07.089"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020712-163949"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213335.40358.47"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181868904"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63708-X"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.2741\/e275"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707704"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2008.01.001"},{"key":"e_1_3_2_11_1","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer CD","year":"1997","unstructured":"Moyer CD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-48","journal-title":"Cancer Res"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(04)00083-2"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0462"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22545"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2009.02.001"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70228-1"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.900542"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00237"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60893-8"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70214-5"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9215"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70391-2"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2821"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.02.039"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0706596"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.812071"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.541"},{"key":"e_1_3_2_31_1","first-page":"31","article-title":"Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients","volume":"62","author":"Klasa-Mazurkiewicz D","year":"2008","unstructured":"Klasa-Mazurkiewicz D, Jarzab M, Milczek T, et al. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients. Pol J Pathol 2008;62:31-40","journal-title":"Pol J Pathol"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-010-9199-4"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2794"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S13071"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6683"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.3178"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70244-X"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5809"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4409"},{"key":"e_1_3_2_44_1","unstructured":"Ledermann J Perren TJ Raja FA et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial [abstract 10]. 2013 European Cancer Congress; 13 September 2013; Amsterdam Netherlands"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.05.033"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7348"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.030271fje"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.5208"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-00009577-200505001-00001"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2308"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2014.862496"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2848"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.541"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq708"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910640412"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc839"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.03.029"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207721"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.1196"},{"key":"e_1_3_2_61_1","first-page":"215","article-title":"Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"115","author":"Behbakht K","year":"2011","unstructured":"Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011;115:215-20","journal-title":"Gynecol Oncol"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1012"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2013.02.003"},{"key":"e_1_3_2_64_1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3892\/mmr.2013.1371","article-title":"Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors","volume":"7","author":"Zhang L","year":"2013","unstructured":"Zhang L, Liu P, Li H. Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors. Mol Med Rep 2013;7:1705-9","journal-title":"Mol Med Rep"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31825736fd"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2004.12.026"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(19970615)65:4<479::AID-JCB4>3.0.CO;2-L"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.07.080"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.7685"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu024"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2251"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.05.022"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0463.2003.1110411.x"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3263"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0071"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.09121"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3282f077b3"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181bda1a7"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu363"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt405"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S55196"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.03.007"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.10.13144"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-16"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMR.S14115"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25423"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2769"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"issue":"5","key":"e_1_3_2_89_1","doi-asserted-by":"crossref","first-page":"abstract 5511","DOI":"10.1200\/jco.2014.32.15_suppl.5511","article-title":"Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum resistant ovarian cancer","volume":"32","author":"Hamanishi J","year":"2014","unstructured":"Hamanishi J, Mandani M, Ikeda T, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum resistant ovarian cancer. J Clin Oncol 2014;32(5s Suppl):abstract 5511","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_90_1","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.18632\/oncotarget.1916","article-title":"Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin","volume":"5","author":"Maleki Vareki S","year":"2014","unstructured":"Maleki Vareki S, Rytelewski M, Figueredo R, et al. Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 2014;5:2778-91","journal-title":"Oncotarget"},{"issue":"5","key":"e_1_3_2_91_1","doi-asserted-by":"crossref","first-page":"abstract 5505","DOI":"10.1200\/jco.2014.32.15_suppl.5505","article-title":"Lurbinectedin (PM01183), an active compound in platinum-resistant\/refractory ovarian cancer (PRROC) patients: results of a two-stage, controlled phase II study","volume":"32","author":"Poveda A","year":"2014","unstructured":"Poveda A, Berton-Rigaud D, Ray-Coquard IR, et al. Lurbinectedin (PM01183), an active compound in platinum-resistant\/refractory ovarian cancer (PRROC) patients: results of a two-stage, controlled phase II study. J Clin Oncol 2014;32(5s Suppl):abstract 5505","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2007.702"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.767328"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2013.11.009"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3248"},{"issue":"5","key":"e_1_3_2_96_1","doi-asserted-by":"crossref","first-page":"abstract 5502","DOI":"10.1200\/jco.2014.32.15_suppl.5502","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley C","year":"2014","unstructured":"Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 2014;32(5s Suppl):abstract 5502","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14047742"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.5068"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2777"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7856"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2015.999154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:16:52Z","timestamp":1772745412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2015.999154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3,4]]}},"alternative-id":["10.1517\/13543784.2015.999154"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2015.999154","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}